toripalimab,porustobart
junshi biosciences,harbour biomed,coherus
['porustobart', 'toripalimab']
 annual conference 2023 programme alert a phase ib dose-expansion study of porustobart, an anti-ctla-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with advanced high-grade #nens 18 apr, tuesday #meded
COR2ED bringing you Independent Medical Education developed 
by NET CONNECT, international experts in neuroendocrine tumors